Solid Lipid Nanoparticles for Brain Targeting

  • Sachin Raosaheb Hangargekar LNCT, University, Bhopal- 462042, MP, India
  • Pradeepkumar Mohanty LNCT, University, Bhopal- 462042, MP, India
  • Ashish Jain LNCT, University, Bhopal- 462042, MP, India


Brain is considered to be highly impermeable barrier, possessing different obstacles like presence of enzymes, presence of tight junctions that limit the entry for most of the drugs. The presence of these obstacles, possess a challenge for administration of the drugs. The conventional means of drug delivery in form of emulsions, fail to overcome these obstacles, and hence there is a need for newer drug delivery approach, that will cross these barriers of the brain. So, these nanoparticles can be an alternative to other conventional systems. They offer several advantages such as improved bioavailability and solubility that are composed of macromolecular materials like lipids and polymers possess low cytotoxicity, high drug loading capability, and good scalability these are the most effective colloidal carriers that have the ability to incorporate drugs into nanocarriers and used as drug targeting to specific area. Thus, this article will emphasise on properties of Blood Brain Barrier, strategies to overcome the blood–brain barrier, literature regarding the use of SLNs in various neurological disease states, production methods of SLN and its evaluation. Hence, these solid lipid formulations can be a new form and one of the promising approach for drug delivery system in future, that have remarkable possibility to cross the BBB.

Keywords: Solid lipid nanoparticles, Nanocarriers, Blood–brain barrier


Download data is not yet available.


1. Bummer PM, Physical chemical considerations of lipid based oral drug delivery — solid lipid nanoparticles, Critical Reviews™ in Therapeutic Drug Carrier System, 2004; 21: 1–20.
2. Muller RH., Keck CM. Challenges and solutions for the delivery of biotech drugs — a review of drug nanocrystal technology and lipid nanoparticles, Journal of Biotechnology, 2004; 113 (1–3):151–170.
3. Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities, Pharmaceutical. Therapeutics, 2004; 104 (1): 29–45.
4. Fundaro A, Cavalli R, Bagoni A, Vighetto D, Zara G.P, Gasco M.R, Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetic and tissue distribution after i.v. administration to rats, Pharmaceutical Research, 2000; 42 (4): 337–343.
5. Chen D, Yang T, Liang W, Zhang Q. In vitro and in vivo study of two types of long circulating solid lipid nanoparticles containing Paclitaxel, Chemical and Pharmaceutical Bulletin ,2001; 49: 1444–1447.
6. Reddy JS, Venkateshwarlu V. Novel delivery systems for drug targeting to the brain, Drugs of Future, 2004; 29 (1): 63–83.
7. Tortora G, Derrickson B. Principles of Anatomy and Physiology. 15th ed. John Wiley and Sons; 2017. P.477-501.
8. Waugh A, Grant A. anatomy and Physiology. 9th edition. Churchill Livingstone; 2001,P. 171-189.
9. Lesniak MS, Brem H. Targeted therapy for brain tumours. Nature Reviews Drug Discovery, 2004; 3:499–508.
10. Stenehjem DD, Hartz AM, Bauer B, Anderson GW. Novel and emerging strategies in drug delivery for overcoming the blood-brain barrier. Future Medicinal Chemistry, 2009,1:1623–1641.
11. Parle P, Aggarwal G, Kumar S. Brain Targeted Drug Delivery System: A Review. World Journal of Pharmacy and Pharmaceutical Sciences, 2016; 5(6): 398-414.
12. Pardridge WM. Blood-brain barrier delivery. Drug Discovery Today, 2007; 12:54–61.
13. Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nature Reviews Neuroscience, 2006; 7:41–53.
14. Pavan B, Dalpiaz A, Ciliberti N, Biondi C, Manfredini S, Vertuani S. Progress in drug delivery to the central nervous system by the prodrug approach. Molecules. 2008; 13: 1035–1065.
15. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiology of Disease, 2010; 37: 48–57.
16. Banks WA, From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nature Reviews Drug Discovery, 2016; 15: 275–292.
17. King A, Breaking through the barrier. Chem World. 2011; 8:36–39.
18. Barua NU, Gill SS, Love S. Convection-Enhanced drug delivery to the brain: therapeutic potential and neuropathological considerations. Brain Pathology, 2014; 24:117–127.
19. Vlieghe P, Khrestchatisky M, Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery. Medicinal Research Reviews, 2013; 33:457–516.
20. Bhaskar S, Tian F, Stoeger T, et al. Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicology, 2010 : 7:3.
21. Chen Y, Dalwadi G, Benson H, Drug delivery across the blood– brain barrier, Current Drug Delivery, 2004; 1: 361–376.
22. Kreuter J, Nanoparticles system for brain delivery of drugs, Advanced Drug Delivery. Reviews, 2001; 47: 65–81.
23. Kante B, Dubois-Krack G, Meester C, Toxicity of polyalkylcyanoacrylate nanoparticles, Journal Pharmaceutical Sciences,1982; 71 :786–789.
24. Limayem I, Fessi H, Purification of nanoparticle suspension by a concentration/diafiltration process, Pure Technology, 2004; 38 : 1–9.
25. Ekambaram P, Priyanka K, Sathali A, Solid Lipid Nanoparticles: A Review. Scientific Reviews And Chemical Communications, 2012; 2(1): 80-102.
26. Bagul U, Pisal V, Solanki N, Current Status of Solid Lipid Nanoparticles: A Review. Modern Applications of bioequivalence & bioavailability, 2018; 3(4) : 1-2.
27. Yasir M, Sara U. Solid lipid nanoparticles for nose to brain delivery of haloperidol: in vivo drug release and pharmacokinetics evaluation. Acta Pharmaceutica Sinica B, 2014; 4 (6) : 455.
28. Mishra M, Bansal K, Verma A. Solid lipid nanoparticles: Emerging colloidal nano drug delivery systems. Pharmaceutics, 2018; 10(19): 1-21.
29. Garud A, Singh D, Garud N. Solid lipid nanoparticles (SLN): Method, Characterization and Applications. International Current Pharmaceutical Journal, 2012; 1(11): 384-393.
30. Abbas H, Refai H, Sayed N,. Superparamagnetic Iron Oxide-Loaded Lipid Nanocarriers Incorporated in Thermosensitive In Situ Gel for Magnetic Brain Targeting of Clonazepam. Journal Pharmaceutical Science, 2018; 107(8):2119-2127.
31. Goppert T, Muller R, Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns, Journal of Drug Targeting, 2005; 13 (3): 179–187.
32. Bhargava S, Bhargava V, Surface Modified Solid Lipid Nanoparticles for the targeted delivery to brain: Management of HIV-1 Associated Dementia, 2018, International Congress. 880.
33. Yasira B, Solid lipid nanoparticles for nose to brain delivery of haloperidol: in vitro drug release and pharmacokinetics evaluation, Acta Pharmaceutica Sinica B, 2014; 4(6):454–463.
34. Jain P, Pandey V, Soni V.Surface Modified Solid Lipid Nanoparticles for Brain Cancer Treatment, Asian Journal of Pharmaceutics, 2019; 13 (2) : 119 – 124.
35. Morsi N, Dalia M. Ghorab A, Brain targeted solid lipid nanoparticles for brain ischemia: preparation and in vitro characterization Pharmaceutical Development and Technology, 2013; 18(3) : 736-744.
36. Wang JX, Sun X, Zhang ZR, Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles, European Journal of. Pharmaceutics and Biopharmaceutics, 2002; 54 (3) : 285–290.
37. Swathi G, Prasanthi NL, Manikiran SS, Ramarao N, Solid lipid nanoparticles: colloidal lipid carrier system for drug delivery. International Journal of Pharmaceutical Sciences and Research, 2010; 1(12): 1-16.
38. Pallerla S, Prabhakar B, A Review on Solid Lipid Nanoparticles. International Journal of Pharmaceutical Sciences Review and Research, 2013; 20(2): 196-206.
83 Views | 369 Downloads
How to Cite
Hangargekar S, Mohanty P, Jain A. Solid Lipid Nanoparticles for Brain Targeting. JDDT [Internet]. 30Aug.2019 [cited 31Oct.2020];9(4-A):911-5. Available from: